Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care
1.5 Credits / Dermatology
View More
Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care
1.5 Credits / Dermatology, Immunology
View More
The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying ...
1.0 Credit / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmacist Credit)
2.0 Credits / Human Trafficking, Law
View More
From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape
August 13, 2025 | 1:00 PM & 8:00 PM EDT
View More
Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape for Managed Care Professionals
August 19, 2025 | 1:00 PM & 8:00 PM ET
View More
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Patients With Chronic Spontaneous Urticaria Seek Better Treatment Beyond Current Options
July 28th 2025Patients with chronic spontaneous urticaria experience inadequate symptom control and significant emotional burdens despite various treatment approaches, highlighting an urgent need for more effective and sustained therapies to improve their quality of life.
Gefurulimab for gMG Meets Key End Points in PREVAIL Trial
The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.
AllergyAware E-Learning Training Program Boosts Anaphylaxis Preparedness in School Staff
July 25th 2025The AllergyAware e-learning course effectively trained school personnel on anaphylaxis management, significantly improving their knowledge and confidence in using epinephrine auto-injectors, despite some technical and pacing issues reported by users.
Across 8 Trials, Ruxolitinib Cream Shows Favorable Safety in Pediatric AD
July 25th 2025A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).
AI-Enhanced ECG Expands Access, Reduces Costs for Patients
July 25th 2025An AI model significantly outperformed cardiologists when reviewing ECGs of structural heart disease and may potentially be a step towards increased access and lower costs for early detection of conditions like heart failure and valvular heart disease.